This section keeps you updated on any major developments throughout the course of the MICROB-PREDICT project. For PDFs of our own press releases about progress within the MICROB-PREDICT project please go to DOWNLOADS. To receive our project newsletter please subscribe here!
23 September 2022
Watch our mini-video series from #ILC2022
We tried something new, check it out: Short video interviews by curious patient representatives from the European Liver Patients’ Association (ELPA) who asked Prof. Dr. Jonel Trebicka, our scientific coordinator, questions about the MICROB-PREDICT, its clinical trial, and its impact. The interviews were conducted during the International Liver Congress (ILC) in London, United Kingdom, in June 2022.
21 September 2022
Bioethics and Law Observatory organises an online seminar
On September 21, 2022, the Bioethics and Law Observatory (OBD) -UNESCO Chair in Bioethics and the Spanish Data Protection Agency (AEPD) jointly organize the seminar “Inteligencia artificial y protección de datos en investigación e innovación en salud: aspectos éticos, legales y sociales”(“Artificial intelligence and data protection in health research and innovation: ethical, legal and social aspects”).
This seminar is part of an agreement between the Bioethics and Law Observatory (OBD) and the Spanish Data Protection Agency.
This event is free and open for anyone, but please note that it will be held in Spanish. For more information click here, find here the program and feel free to register here for your online attendance.
24 June 2022
Meet us at ILC2022 on 24/06/2022, 12-13h GMT!
Don`t miss the opportunity to meet the team and receive important information about the project at ILC2022 at the EASL Community Hub! Read more.
18 March 2022
4th General Assembly Meeting, Mallorca
Our 4th GA meeting, taking place from 15-18 March 2022 in Mallorca has been successfully completed.
The first 1.5 days were reserved for our first MICROB-PREDICT paper-writing workshop. 35 scientists from all over Europe discussed 12 papers about ACLF and microbiome in four different places face-to-face and virtual at the same time!
The other days were dedicated to hear further updates and results from our different work packages. With 54 participants joining on-site and almost 20 participants remotely the meeting was a great success. Thank you all for taking part!
28 January 2022
MICROB-PREDICT co-organised Falk Symposium on Alcoholic Liver Disease
From 27-28 January 2022, consortium members Prof. Aleksander Krag (OUH) and Prof. Rajiv Jalan (UCL) as well as members of the scientific and ethical advisory board (SEAB), including Dr. Vijay Shah (Mayo Clinic) and Prof. Bernd Schnabl (UCSD) presented and discussed the newest research results and pressing questions regarding the treatment and recovery from alcoholic liver disease, while MICROB-PREDICT coordinator Prof. Jonel Trebicka (GUF), who had co-organised the online symposium, served as chairman of Session II on “Alcoholic hepatitis, liver failure, and systemic disturbance” and the poster session.
11 November 2021
Nationwide population-based study (2005 to 2018) of 250 million hospital admissions in Germany reveals changed trends and the course of liver cirrhosis and its complications
Scientists from Goethe University Hospital Frankfurt under leadership of Prof. Jonel Trebicka analyzed the data from the Federal Statistical Office of Germany of around 250 million hospital admissions in Germany from 2005 to 2018 and found out that the number of hospital admissions with cirrhosis has increased nationwide, and its diagnosis as a comorbidity doubles the mortality rate of other chronic diseases.
All results of this nationwide study published in “The Lancet Regional Health – Europe”, demonstrate the need for development of strategies to improve care in cirrhosis to decrease this considerable healthcare burden.
2 November 2021
Save-the-date: 27. Frankfurter Leber-Forum
Under the slogan “Patients ask – Doctors answer” the 27. Frankfurter Leber-Forum will take place on November 24th, 2021 from 05.00 – 07.00 p.m. (CET).
Speakers will present short talks on various topics, including fatty liver, liver cirrhosis and viral hepatitis. Online participation will be free of charge.
28 October 2021
Great session about non-etiological therapies in the course of cirrhosis chaired by MICROB-PREDICT
Coordinator, Jonel Trebicka: the panel presented several statements about
1. the use of statins, aspirin, albumin and rifaximin in patients with liver cirrhosis.
2. the literature for the use of statins, aspirin and albumin in the view of gut-liver-axis (Wim Laleman, partner)
3. evidence and future direction of the use of microbiome-based biomarker to guide the treatment of patients, e.g.albumin (Aleksander Krag, WP Leader and EASL vice-secretary)
4. rationale and data on the role of microbiome changes for development of complications of cirrhosis (Jasmohan Bajaj, Collaborator).
For more information, reach out!
27 October 2021
BavenoVII Consensus Workshop sponsored by MICROB-PREDICT
MICROB-PREDICT supports this year`s BavenoVII Consensus Workshop. Baveno Workshops have been held every 5 years from 1990 till today. Each time, important advances have been made in understanding the pathophysiology of portal hypertension, as well as in developing new treatments and new strategies for the management of advanced cirrhosis and portal hypertension. See programme.
14 October 2021
Camila Alvarez-Silva appointed as new chair of the Early Career Scientists group
We congratulate Camila Alvarez-Silva from University of Copenhagen for having been appointed as new chair of the MICROB-PREDICT Early Career Scientists group. She takes this important position over from her predecessor Annelotte Broekhoven (LUMC) who was the chair in the third year of the project.
Thanks to Annelotte for her efforts to coordinate the training activities during the 3rd year which included amongst other things the organisation of the 2nd masterclass!
8 October 2021
3rd General Assembly Meeting, Leuven, Belgium
Our first hybrid-GA meeting, taking place from 6-8 October 2021 in Leuven, Belgium has been successfully completed with 37 participants joining on-site, and over 20 participants remotely.
A lot of data has been presented with promising multiomics results to develop biomarkers to predict disease progression and response to treatment for patients suffering from cirrhosis and ACLF.
2 September 2021
Successful MICROB-PREDICT Online Symposium connected to EASL School on Hepatology 2021
Successful MICROB-PREDICT and DECISION – Online Symposium ‘Management of acute-on-chronic liver failure’ on Thursday, 2nd September 2021 from 12.30 – 16.30h CEST which was organised at the occasion of the EASL School of Hepatology.
At this symposium, several experts of both project consortia presented recent advances in the fields of microbiome research and systems medicine, introduced the role of proteomics and metabolomics in hepatology and discussed treatment strategies and their mechanisms of action in acute-on-chronic liver failure.
With almost 100 registered attendees and speakers from 37 countries our symposium was a great success and we would like to thank everyone for their participation and the lively discussions.
8 July 2021
MICROB-PREDICT Symposium connected to EASL School on Hepatology 2021
We would like to invite you for the MICROB-PREDICT online symposium on ‘Management of acute-on-chronic liver failure’, which will take place on 2nd September 2021, in the afternoon before the EASL School of Hepatology.
Course director: Prof. Wim Laleman
Date: Thursday, 02 September 2021
29 June 2021
MICROB-PREDICT project partners at the IHMC 2021
We are pleased that four of our MICROB-PREDICT project partners gave a talk at this year’s virtual International Human Microbiome Consortium Congress 2021 (IHMC 2021), which took place from June 27-29, 2021.
Stanislav Dusko Ehrlich – ‘Oral Microbiome in Health and Disease‘
Peer Bork – ‘The Impact of Drugs on Human Gut Microbial Communities‘
Mani Arumugam – ‘Revealing the Hidden Biodiversity of the Human Gut Microbiota‘
Jonel Trebicka – ‘Gut Microbiome and End-Stage Liver Disease‘
24 June 2021
ILC 2021: Symposium „Old and new treatments for patients with advanced cirrhosis”
Very successful symposium on Thursday, 24th June 2021 from 14-15h CEST organised by members of MICROB-PREDICT in the frame of the virtual ILC congress. Topics included:
- Why and how to modulate the microbiome: example from MICROB-PREDICT study (Shawcross)
- Old drugs for novel treatment strategies (Posé)
- Human albumin: from established indications to novel perspectives (Caraceni)
- System medicine: is it the right track to personalized treatments: example from DECISION study? (Trebicka)
10 June 2021
MICROB-PREDICT at the International Liver Congress 2021!
SAVE THE DATE: ILC 2021 will take place from Wednesday to Saturday, 23–26 June. Register now and visit our MICROB-PREDICT booth.
Click here for more information!
9 June 2021
Successful patient event on 9th June
27 representatives of national patient organisations from 10 European countries listened to talks about therapies for cirrhosis and ACLF, research needs and outlook for the future. A lot of interest was shown towards available and new therapies for decompensated cirrhosis and ACLF. The event was organised by ELPA (president Marko Korenjak) and chaired by Prof. Rajiv Jalan, scientific director of EFCLIF.
11 May 2021
Workshop on “Health and economic benefits of microbiomes” with the EU Parliament
MicrobiomeSupport is organising an online workshop with the Panel for the Future of Science and Technology (STOA) at the European Parliament. This virtual event will, among other things, present state-of-the-art microbiome research and address safety and regulatory pathways of microbiome innovations. The workshop will take place virtually on 11th May 2021, between 14:00 and 16:30 CEST.
For further information and registration, click here.
5 May 2021
Article on “Microbiome and Nanotechnology” got frontispiece of Advanced Materials
Congratulations to Arben Merkoçi and co‐workers, whose article on “Microbiome and Nanotechnology: The Microbiome Meets Nanotechnology: Opportunities and Challenges in Developing New Diagnostic Devices” got frontispiece of Advanced Materials (Adv. Mater. 18/2021). In this article, Arben and his team consider the unique properties of nanomaterials that will enable, in the near future, the development of point‐of‐care sensors for the detection of microbiome‐related biomarkers. Read full article.
1 February 2021
Annelotte Broekhoven appointed as new chair of the Early Career Scientists group
We congratulate Annelotte Broekhoven from Leiden University Medical Center for having been appointed as new chair of the MICROB-PREDICT Early Career Scientists group. She takes this important position over from her predecessor Romy Zwittink (also LUMC) who was the chair in the second year of the project, after Robert Schierwagen from Goethe University Frankfurt, who successfully filled this role in the first year. It will be Annelotte`s task to coordinate the training activities during the 3rd year which include amongst other things the organisation of the 2nd masterclass.
25 January 2021
5th Steering Committee Meeting held online
20 members of the MICROB-PREDICT Steering Committee met online on 25-26 January to discuss first multiomics and very interesting animal results. Corona slowed things down in 2020, but the project is still progressing very well thanks to the amazing work of all our 22 partner institutions and about 100 involved scientists.
30 November 2020
Nature Reviews: Utilizing the gut microbiome in decompensated cirrhosis and acute- on- chronic liver failure
Read the latest nature reviews article which focuses on the possible pathogenic, diagnostic and therapeutic role of the gut microbiome in decompensation of cirrhosis and progression to ACLF by Jonel Trebicka, Peer Bork, Aleksander Krag and Manimozhiyan Arumugam. Read more.
19 November 2020
PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis
Proven bacterial infections and severe alcoholic hepatitis, alone or in combination, are the major precipitating events for acute decompensation and ACLF. While the type of precipitating event has no association with survival, the number of identifiable events was significantly associated with surrogates of systemic inflammation and increased 90-day mortality. Adequate first-line antibiotic treatment of proven bacterial infections was associated with lower ACLF development rate and higher 90-day survival. Specific preventive and therapeutic strategies to precipitating events may improve outcome in decompensated cirrhosis. Read more.
19 October 2020
Targeting the gut-liver-immune axis to treat cirrhosis
Thomas Tranah and colleagues from King`s College London publish a review about links between cirrhotic dysbiosis, intestinal barrier dysfunction and deficits of host-microbiome compartmentalisation and mucosal immune homoeostasis that occur in settings of advanced chronic liver disease. Read more.
2 October 2020
New MICROB-PREDICT Masterclass video on „The human gut microbiome in health and disease” by Prof. Peer Bork
Prof. Peer Bork’s speaks about the latest advances in microbiome research as part of the MICROB-PREDICT project. The talk was recorded at the occasion of the first MICROB-PREDICT MasterClass in Frankfurt.
3 September 2020
Paper by Olaf Tyc et al. published on the cover page of Liver transplantation
Congratulations to Olaf and co-workers! The article on “Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease” by Olaf Tyc et al. made it to the cover page of Liver transplantation (Volume 26, Issue 12). Congratulations to all for the great achievement! Read full article.
27 August 2020
Who are the people behind the science of MICROB-PREDICT?
Watch this video to meet the coordinator, the patient representative, our leading researchers, clinicians, and the management team. Feel free to like and share to promote our research and efforts. We are all working together to improve the lives of patients suffering from decompensated cirrhosis and ACLF.
26 August 2020
MICROB-PREDICT in 3 minutes – Prof. Dr. Jonel Trebicka summarises the project at EASL’s “Digital ILC 2020”
14 July 2020
The PREDICT study uncovers three clinical courses in acutely decompensated cirrhosis with distinct pathophysiology
Data from 1071 patients with acute decompensation reveals patterns that allow grouping patients into three different clinical courses with different mortality. The investigators have determined that the development of systemic inflammation is key to the progression of the disease and affects patients with pre-ACLF. Half of them die in three months and seven out of ten in 1 year. Read more.
10 July 2020
Marko Korenjak is being interviewed about MICROB-PREDICT by Maja Thiele
Former “radio moderator”-turned-“medical hepatologist” Prof. Dr. Maja Thiele from Odense University Hospital (OUH) in Denmark interviews Marko Korenjak, the current president of the European Liver Patients’ Association (ELPA) about his hopes in MICROB-PREDICT and why this is such a special research consortium. Watch and share the whole 5min-video on YouTube: It’s absolutely worth it!
9 July 2020
PDFs of 1st Patient Event Presentations available for download
The PDFs of the 3 presentations by Profs. Jonel Trebica, Aleksander Krag, and Minneke Coenraad are now freely accessible on the DOWNLOADS page. Alternatively, just click on the respective screenshot below to view the desired presentation in your browser.
16 June 2020
SAVE THE DATE – First online patient event on 8 July 2020!
We kindly invite you to the first online patient event of the MICROB-PREDICT project: On Wednesday, 8 July 2020, from 10:30-11:30 AM, we would like to inform you and other cirrhosis patients on our project and its implications for the future management of patients with cirrhosis and discuss with you how to best disseminate this information in the national patient associations. We look forward to meeting you virtually at July 8th!
28 May 2020
New ACLF review article in the New England Journal of Medicine!
Three clinical experts on ACLF just published a joint review article on “Acute-on-Chronic Liver Failure”. Thanks to Vicente Arroyo, Richard Moreau, and Rajiv Jalan for this excellent review and for highlighting the importance of increased clinical research and efforts to prevent decompensated cirrhosis and ACLF. The article was published today in the New England Journal of Medicine (volume 382(22): pages 2137-2145; doi: 10.1056/NEJMra1914900)
26 May 2020
Video of the 1st MICROB-PREDICT Masterclass on „ Acute-on-Chronic Liver Failure (ACLF)” by Prof. Dr. Jonel Trebicka
Prof. Dr. Jonel Trebicka, project coordinator on behalf of EFCLIF and Professor for translational hepatology at the Department of Internal Medicine I, University Clinic Frankfurt speaks about current status and recent advances of ACLF research. The talk was recorded on 20 January 2020 at the occasion of the first MICROB-PREDICT MasterClass in Frankfurt.
1 April 2020
Model describing typical treatment paths in decompensated cirrhosis
Prof. Hans Olav Melberg from UiO concludes an important step and releases a report about typical treatment paths in decompensated cirrhosis, information about the probability of going from one state to another, as well as the costs and quality of life in patients in each state.
1 April 2020
Important ethics deliverables published
Prof. Itziar de Lecuona, leader of the ethics WP, and colleagues publish three important ethics deliverables of MICROB-PREDICT: Informed consent templates for use of human biological samples and personal data in biomedical research, Public engagement strategy to design MICROB-PREDICT along with the need of patients and Codes of conduct applicable and research integrity policy including publications in journals.
22 January 2020
Successful 2nd General Assembly Meeting in Königstein
From 20th-22nd January 2020, 71 delegates of the MICROB-PREDICT consortium met in Königstein near Frankfurt a.M., Germany, to discuss the progress and results after the end of the first year of the project. We are happy to conclude that the project is in schedule and the first results come in nicely.
20 January 2020
First master class for Early Career Scientists
On 20th January 2020, 48 participants of the MICROB-PREDICT Consortium, of which 24 Early Career Scientists attended the first master class which was organized as part of the WP9 training programme before the start of the 2nd General Assembly Meeting, in the hospital of the Goethe University Frankfurt, Germany. Talks included “How to write a successful grant application” (Ameli Schwalber and Jonel Trebicka), “ACLF: current status and recent advances” (Jonel Trebicka) and “Microbiome: current standards and challenges” (Peer Bork). Overall, the feedback was positive, and this format will be repeated again at future General Assembly meetings.
6 November 2019
Big data and artificial intelligence (AI)
Big data and artificial intelligence (AI) are not the future, they are the present. Our ethics WP Leader Prof. Itziar de Lecuona speaks about “Big Data and Artificial Intelligence: Opportunities for Clinical Decision-Making and Health Care Assessment”.
17 October 2019
Policy for integrating the six agendas of responsible research and innovation
Read our policy on how we implement responsible research and innovation of our six agendas (ethics, gender equality, public engagement, governance, scientific education and open access) in MICROB-PREDICT. Our legal and ethics team explains measures to take into account regarding governance, ethics, gender equality, public engagement, open access and scientific education. Download the policy here.
6 September 2019
All PREDICT samples have been shipped to our specialty labs
All PREDICT samples have been shipped to our specialty labs. The majority of proteomics and metabolomics measurements are complete. Congratulations WP3!
2 July 2019
First important milestones achieved
MICROB-PREDICT partners received ethics approvals for shipment of samples. More than 700 samples have been aliquoted and were shipped to specialty labs. Now, data generation begins.
30 June 2019
MICROB-PREDICT Informed consent policy
The MICROB-PREDICT policy for human subjects, samples and data describes the ethical and legal framework for the planned research interventions, the implications for research participants and obligations for those conducting research. Download the policy here.
26 March 2019
First internal meeting on specifics of biosensor development
The first meeting of work package 5 (WP5) members dedicated to
validationof biomarkers and biosensor development was held at the Catalan Institute of Nanoscience and Nanotechnology (ICN2) in Barcelona. The aim was to initiate collaboration of ICN2 and the French Alternative Energies and Atomic Energy Commission (CEA) for the development of point-of-care (POC) diagnostic tests.
1 January 2019
MICROB-PREDICT kicks off!
Today, the 6-year long, pan-European research project begins. All of us are excited to roll up our sleeves and get to work!